EXAS vs ROIV · rev $2.76B vs rev $8.3M
EXACT Sciences Corporation (EXAS) versus Roivant Sciences Ltd (ROIV) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Roivant Sciences Ltd (ROIV) is a biotechnology company listed on US.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
Latest reported ROIV revenue for 2026-03-31 was $8.3M. Net income was -$299.8M. Revenue was down 71.6% from 2025-03-31 to 2026-03-31. ROIV currently screens at market cap $7.47B.
EXAS currently screens at market cap $20.03B. ROIV currently screens at market cap $7.47B.
Not investment advice. Open the EXAS and ROIV stock pages for the full models.
Not investment advice.